December 21st, 2006
Velcade+ Doxil: Better than Velcade Alone in Slowing Progression of Multiple Myloma
In a phase II trial led by a University of North Carolina at Chapel Hill School of Medicine researcher found that a newly formulated chemotherapy drug Doxil (doxorubicin delivered via liposomes, or microscopic fat bubbles) combined with standard therapy Velcade slows the progression of multiple myeloma better than Velcade alone.
Multiple myeloma is an advanced cancer […]
Recent Comments